Recent Data Projects Growth in the Legal Cannabis Market

PR Newswire

NEW YORK, March 22, 2017 /PRNewswire/ --

According to a report by the New Frontier Data, the legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% or reaching more than $24 billion by 2025. The medical cannabis market is projected to grow at 12% CAGR through 2025, or growing from $4.7 billion in 2016, to an estimated $13.3 billion in 2025. These projections do not include assumptions for additional states, which may come into the picture before 2025. ChineseInvestors.com, Inc. (OTC: CIIX), MassRoots Inc. (OTC: MSRT), 22nd Century Group Inc. (NYSE: XXII), United Cannabis Corporation (OTC: CNAB), CV Sciences Inc. (OTC: CVSI)

New Frontier CEO & Founder Giadha Aguirre De Carcer pointed out the work that was done in Washington State in their approach towards the legal cannabis market, and the possible similar achievements of other states in the future. "We applaud, in particular, the work of Washington state which has set the gold standard in transparency by making all the data collected by its seed-to-sale system publicly available. This level of transparency is enormously valuable as it enables all stakeholders across the industry, including operators, investors, regulators and policymakers to have a quantifiable view into this highly dynamic industry," said Giadha Aguirre De Carcer.

ChineseInvestors.com, Inc. (OTCQB: CIIX) is a premier financial information website for Chinese-speaking investors. On March 20th, the company announced, "that it has established and registered XiBiDi Biotechnology Co., Ltd. in the Pudong Free-Trade Area in Shanghai, with registered capital requirements of $1.45 million USD over the next 10 years. XiBiDi Biotechnology will focus on the online and offline sales of health products including hemp-derived CBD (cannabidiol) oil, as well as hemp-based food and beverages. Notably, the Chinese character 'XiBiDi' is homophonic to 'CBD' in English."

"I am delighted about the establishment and registration of our new hemp company," says CIIX founder and CEO, Warren Wang. "XiBiDi Biotechnology is strategically located in the Pudong Free-Trade Area of Shanghai, China, where we have the opportunity to reach a consumer base of nearly 1.4 billion people. We believe that this large population affords XiBiDi an outstanding opportunity to be the provider of choice for natural hemp products."

ChineseInvestors indicated that, "XiBiDi Biotechnology will be the operator of CIIX's recently launched CBD online store, www.ChineseCBDoil.com , which will primarily focus on selling, where legal, hemp-based CBD nutrient and health products to Chinese-speaking customers worldwide through the online retail process. CIIX is also in preparations to open a retail store based in the predominantly Chinese community of San Gabriel, California."

Leading technology platform for the medical cannabis industry, MassRoots Inc. (OTCQB: MSRT), has reached a milestone of over one million registered users on its platform. Through its mobile application, MassRoots enables consumers to rate products and strains based on their efficacy and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary. "MassRoots registering one million users is a significant milestone made possible by the strong support of our shareholders, tireless work of the MassRoots team, and passion of cannabis consumers worldwide," stated MassRoots Chairman and CEO, Mr. Isaac Dietrich. "In the coming days, we'll be releasing a revamped website and updates to our mobile application that will significantly enhance our user experience and can be immediately deployed to our vast user base. With the 4/20 holiday season rapidly approaching, we're preparing for a surge of web traffic, media coverage and user registrations that MassRoots has historically experienced this time of year. We look forward to continuing to expand our market share of cannabis consumers and dispensaries to further drive shareholder value."

22nd Century Group Inc. (NYSE: XXII) is a plant biotechnology company with a goal to reduce the harm caused by smoking. The company's focus is the research, development, licensing, manufacturing, and worldwide sales and distribution of its products. 22nd Century Group's proprietary genetic engineering technology and plant breeding expertise allows them to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. The company's subsidiary, Botanical Genetics, is focused on natural, safe and effective cannabis-based products for human health, well-being and nutrition, in addition to industrial products refined from cannabis.

United Cannabis Corporation (OTCQB: CNAB) is engaged in medical spa management business. The Company focuses on providing products, services and intellectual property to the cannabis industry. The Company focuses on advancing the use of phytocannabinoid therapeutics in medicine through research, product development and education. The Company's Prana Bio Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purpose. These products, licensed to regulated marijuana dispensaries, are broken into 5 categories that are available in capsules, sublingual's, and topical delivery methods. The Company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability.

CV Sciences Inc. (OTCQB: CVSI) focuses on drug development activities on products containing cannabidiol (CBD) as the active pharmaceutical ingredient, and also is engaged in the sale of CBD, and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand, the leading hemp-derived CBD product line in the United States. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company's specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com